JOHNSON & JOHNSON — Form 8-K
Filed July 15, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 28/100
What the filing says
Johnson & Johnson reported Q2 2026 sales of $25.310 billion (6.6% reported growth, 5.6% operational growth) versus Q2 2025 sales of $23.743 billion. The company raised full-year 2026 guidance to $101.1 billion (7.3% growth at midpoint) from prior April guidance of $100.8 billion (7.0% growth), and increased adjusted EPS guidance by $0.13 to $11.68 (8.2% growth). Innovative Medicine segment grew 6.8% operationally; MedTech grew 3.6%. Key drivers included DARZALEX, TREMFYA, CAPLYTA, and TECVAYLI in pharma; wound closure and biosurgery in MedTech. STELARA declined 55.7% operationally due to patent loss; IMBRUVICA declined 20.2% operationally. The company also announced $650–$750M supply chain restructuring program in Innovative Medicine through end-2029.
Why this rating
Q2 beat and guidance raise are routine for large caps; $25.3B quarter is 6.9% of $367B market cap—normal quarterly performance. No M&A, no structural change.
See more from July 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.